Amgen's quick Aimovig launch boosts blockbuster hopes for Lilly, Teva and Alder: analyst

20th August 2018 Uncategorised 0

Amgen’s Aimovig is riding a big wave of early demand, and launch trends for the migraine prevention drug “bode well” for its forthcoming rivals, an analyst wrote—so much so that peak sales estimates for the whole class have ballooned to $6.9 billion.

More: Amgen's quick Aimovig launch boosts blockbuster hopes for Lilly, Teva and Alder: analyst
Source: fierce